Further evidence supporting antibody-based RHAMM targeting was provided by Pilarski et al., who demonstrated that a monoclonal antibody against RHAMM markedly suppressed HA-induced locomotion of malignant B cells derived from patients with hairy cell leukemia [100]. This evidence concerns the gene HMMR and hairy cell leukemia.